Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 294

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Implantable Cardioverter/Defibrillator Therapy in Arrhythmogenic Right Ventricular Cardiomyopathy: Single-Center Experience of Long-Term Follow-Up and Complications in 60 Patients

Open access
Wichter, Thomas, Paul, Matthias, Wollmann, Christian, Acil, Tayfun, Gerdes, Petra, Ashraf, Obaidullah, Tjan, Tonny D.T., Soeparwata, Rasijd, Block, Michael, Borggrefe, Martin, Scheld, Hans H., Breithardt, Günter, Böcker, Dirk·2004·Circulation

Abstract

Background— Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a major cause of ventricular tachycardia (VT) and cardiac arrest in young patients. We hypothesized that treatment with implantable cardioverter/defibrillators (ICDs) is safe and improves the long-term prognosis of ARVC patients at high risk of sudden death. Methods and Results— Sixty patients with ARVC (aged 43±16 years) were treated with transvenous ICD systems. Despite a higher number of right ventricular sites tested for adequate lead positions ( P <0.05), lower R-wave amplitudes ( P <0.001) were achieved in ARVC patients compared with other entities. During follow-up of 80±43 months (396 patient-years), event-free survival was 49%, 30%, 26%, and 26% for appropriate ICD therapies and 79%, 64%, 59%, and 56% for potentially fatal VT (>240 bpm) after 1, 3, 5, and 7 years, respectively. Multivariate analysis identified extensive right ventricular dysfunction as an independent predictor of appropriate ICD discharge. Fifty-three adverse events occurred in 37 patients during the perioperative (n=10) or follow-up (n=43) period, mainly related to the leads (n=31 in 21 patients). No lead perforation was observed. Freedom from adverse events was 90%, 78%, 56%, and 42% and freedom from lead-related complications was 95%, 85%, 74%, and 63% after 1, 3, 5, and 7 years, respectively. Conclusions— These results strongly suggest an improvement in long-term prognosis by ICD therapy in high-risk patients with ARVC. However, meticulous placement and long-term observation of transvenous lead performance with focus on sensing function are required for the prevention and/or early recognition of disease progression and lead-related morbidity during long-term follow-up of ICD therapy in ARVC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.0000121738.88273.43

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 294

Metadata

Authors
Wichter, T., Paul, M., Wollmann, C., Acil, T., Gerdes, P., Ashraf, O., Tjan, T. D. T., Soeparwata, R., Block, M., Borggrefe, M., Scheld, H. H., Breithardt, G., & Böcker, D.
Venue
Circulation
Published
2004-03-30
Volume
109
Issue
12
Pages
1503-1508
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2105696323
Cited by
294
References
20
FWCI
12.80
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Implantable Cardioverter/Defibrillator Therapy in Arrhythmogenic Right Ventricular Cardiomyopathy: Single-Center Experience of Long-Term Follow-Up and Complications in 60 Patients. https://app.cochat.ai/papers/10.1161/01.cir.0000121738.88273.43
The paper
Wichter, T., Paul, M., Wollmann, C., Acil, T., Gerdes, P., Ashraf, O., Tjan, T. D. T., Soeparwata, R., Block, M., Borggrefe, M., Scheld, H. H., Breithardt, G., & Böcker, D. (2004). Implantable Cardioverter/Defibrillator Therapy in Arrhythmogenic Right Ventricular Cardiomyopathy: Single-Center Experience of Long-Term Follow-Up and Complications in 60 Patients. Circulation. https://doi.org/10.1161/01.cir.0000121738.88273.43

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.